Victoria M. Cruz

Victoria M. Cruz

Auto-generated profile, based on publicly available information

Victoria M. Cruz

Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2025 in Science
Verified
Journal Article
Closed access
KSKoichi Sato
Koichi Sato
JLJing Lyu
Jing Lyu
JBJeroen van Den Berg
Jeroen van Den Berg
DBDiana Braat
Diana Braat
VCVictoria M. Cruz
Victoria M. Cruz
PKPuck Knipscheer
Puck Knipscheer
G-quadruplexes (G4s) are prevalent DNA structures that regulate transcription but also threaten genome stability. How G4 dynamics are controlled remains poorly understood. Here, we report that RNA transcripts govern G4 landscapes through coordinated G-loop assembly and disassembly. G-loop assembly involves activation of the ATM and ATR kinases, followed by homology-directed invasion of RNA opposite the G4 strand mediated by BRCA2 and RAD51. Disassembly of the G-loop resolves the G4 structure through DHX36-FANCJ–mediated G4 unwinding, which triggers nucleolytic incision and subsequent hybrid strand renewal by DNA synthesis. Inhibition of G-loop disassembly causes global G4 and R-loop accumulation, leading to transcriptome dysregulation, replication stress, and genome instability. These findings establish an intricate G-loop assembly-disassembly mechanism that controls G4 landscapes and is essential for cellular homeostasis and survival.

27 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
JBJuliane L. Buhl
Juliane L. Buhl
JKJannet Koelewijn
Jannet Koelewijn
SMStijn De Munter
Stijn De Munter
VCVictoria M. Cruz
Victoria M. Cruz
DCDaryl Jun Kai Chin
Daryl Jun Kai Chin
CJClaudia Yvonne Janda
Claudia Yvonne Janda
Malignant rhabdoid tumors are highly aggressive pediatric malignancies with limited treatment options and poor outcomes. To expand therapeutic options, we employed mass spectrometry-based cell surface proteomics on malignant rhabdoid tumor and patient-matched normal kidney organoids to identify potential CAR T cell targets. Integrating these findings with transcriptomics and protein expression data, we revealed ROBO1 as a promising target, showing strong and uniform expression across malignant rhabdoid and other pediatric tumors. ROBO1-targeted CAR T cells displayed potent anti-tumor activity in vitro , effectively eliminating tumor cells in co-cultures with organoids from malignant rhabdoid tumors, rhabdomyosarcoma, and neuroblastoma. In vivo, ROBO1 CAR T cells infiltrated tumors, induced potent tumor regression and significantly increased survival in malignant rhabdoid tumor-bearing mice. These findings establish ROBO1 as a compelling therapeutic target for CAR T cell therapy and offer a promising approach to address the critical need for effective treatments in high-risk pediatric solid tumors. Statement of significance: This study identifies ROBO1 as a promising CAR T cell target for pediatric solid tumors. Using patient-derived tumor organoids and tissues, we demonstrate strong ROBO1 expression across several tumor entities and robust anti-tumor efficacy of ROBO1-targeted CAR T cells in vitro and in vivo , underscoring its potential for clinical translation.

23 September 2025 in Nucleic Acids Research
Verified
Journal Article
Open access
RSRoxanne V van der Sluijs
Roxanne V van der Sluijs
AVAlexander E E Verkennis
Alexander E E Verkennis
MHMichael R Hodskinson
Michael R Hodskinson
JBJamie Barnett
Jamie Barnett
VCVictoria M Cruz
Victoria M Cruz
PKPuck Knipscheer
Puck Knipscheer
DNA interstrand crosslinks (ICLs) are highly cytotoxic lesions that block essential cellular processes like replication and transcription. Endogenous ICLs can be induced by reactive aldehydes produced during normal cellular metabolism. Defective repair of these aldehyde-induced ICLs is associated with Fanconi anaemia (FA), a cancer predisposition syndrome. We previously showed that acetaldehyde-induced ICLs are repaired by the FA pathway and a novel excision-independent pathway. Here, we demonstrate that ICLs induced by acrolein, another cellular aldehyde, are also repaired by both pathways, establishing the generality of aldehyde ICL repair. Focusing on the FA pathway, we identify DNA polymerase kappa (Polκ) as the primary translesion synthesis (TLS) polymerase responsible for the insertion step during lesion bypass of unhooked aldehyde ICLs. This function requires Polκ’s catalytic activity and PCNA interaction domains but is independent of Rev1 interaction. In contrast, Polκ has a non-catalytic role in the extension step of cisplatin ICL repair that is dependent on Rev1 interaction. Our work reveals a key role for Polκ in aldehyde ICL repair and provides mechanistic insights into how different ICL structures determine the choice of TLS polymerases during repair.

31 October 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
JBJuliane L. Buhl
Juliane L. Buhl
JKJannet Koelewijn
Jannet Koelewijn
CHCharlotte Op ’T Hoog
Charlotte Op ’T Hoog
LYLi Yang
Li Yang
SMStijn De Munter
Stijn De Munter
CJClaudia Y. Janda
Claudia Y. Janda
Malignant rhabdoid tumors are highly aggressive pediatric malignancies with limited treatment options and poor outcomes. To expand therapeutic options, here we employ mass spectrometry-based cell surface proteomics on malignant rhabdoid tumor and patient-matched normal kidney organoids to identify potential CAR T cell targets. Integrating these findings with transcriptomics and protein expression data, we identify ROBO1 as a promising target, showing strong and uniform expression across malignant rhabdoid tumors and other pediatric tumors. ROBO1-targeted CAR T cells display potent anti-tumor activity in vitro, effectively eliminating tumor cells in co-cultures with organoids from malignant rhabdoid tumors, rhabdomyosarcoma, and neuroblastoma. In vivo, ROBO1 CAR T cells infiltrate tumors, induce potent tumor regression and significantly increase survival in malignant rhabdoid tumor-bearing mice. These findings establish ROBO1 as a therapeutic target for CAR T cell therapy and offer a promising approach to address the unmet need for effective treatments in high-risk pediatric solid tumors.